TRACY MURPHY (TORONTO)
LEUKEMIA STEM CELL SIGNATURES IN ACUTE MYELOID LEUKEMIA
Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the bone marrow. Leukemia stem
cells (LSCs) lead to the development of AML and in many cases lead to disease
relapse. However, their impact is variable and additional parameters can contribute to leukemia
stemness including transcriptional networks, epigenetic alterations and genetic diversity. Leukemia
stem cell signatures have been developed to assess stemness and can potentially risk stratify
treatment approaches.
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES